Jun Tan
18Patents
3h-index
22Co-inventors
60Inventor score
Filing activity: Jun 1, 2000 → Jun 5, 2019
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8778986B1 | Treatment of glycogen synthase kinase-based disease | Human Necessities | 6 | Active |
| US7052852B1 | CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker in alzheimer's disease | Physics | 4 | Expired |
| US8008539B1 | Generation of transgenic human soluble amyloid precursor protein alpha expressing mice | Human Necessities | 3 | Active |
| US8778894B2 | Luteolin and diosmin/diosmetin as novel STAT3 inhibitors for treating autism | Human Necessities | 3 | Active |
| US6787318B1 | Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology | Emerging Cross-Sectional Technologies | 2 | Expired |
| US8802638B1 | Flavonoid treatment of glycogen synthase kinase-based disease | Human Necessities | 1 | Active |
| US9238149B2 | Prevention and treatment of alzheimer'S disease through electromagnetic field exposure | Human Necessities | 1 | Active |
| US7442394B2 | Combined effects of nutrients on proliferation of stem cells | Human Necessities | 1 | Active |
| US8574640B2 | Combined effects of nutrients on proliferation of stem cells | Human Necessities | 1 | Active |
| US10039785B2 | HUCBC treatment of amyloid-associated disease | Human Necessities | 0 | Active |
| US10098909B2 | Ionic cocrystal of lithium, lispro, for the treatment of fragile X syndrome | Human Necessities | 0 | Active |
| US9926354B2 | Amyloid precursor protein (APP) based Ã#-secretase inhibitor peptides, and methods of use | Chemistry; Metallurgy | 0 | Active |
| US9402870B2 | HUCBC treatment of amyloid associated disease | Human Necessities | 0 | Active |
| US10828312B2 | Lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions, and methods of treatment for Alzheimer's disease and neurological disorders | Human Necessities | 0 | Active |
| US9603869B2 | Lithium co-crystals and an additional neuropsychiatric agent for treatment of neuropsychiatric disorders | Human Necessities | 0 | Active |
| US10149982B2 | Prevention and treatment of brain diseases and disorders related to abnormal protein aggregation through electromagnetic field treatment | Human Necessities | 0 | Active |
| US8906414B1 | Methods and compositions for improving bioavailability of epigallocatechin gallate (EGCG) | Human Necessities | 0 | Active |
| US9827285B1 | Compositions and methods of improving cognitive performance | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.